Actively Recruiting
Led by Beijing Tiantan Hospital · Updated on 2026-03-06
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are evaluating the effectiveness of liposomal bupivacaine combined with bupivacaine compared to bupivacaine alone for managing pain after video-assisted thoracoscopic surgery (VATS), a less invasive lung surgery. The study addresses the high rate of acute pain after VATS, which can lead to chronic pain and affect recovery and quality of life if not properly managed. Current evidence on the superiority of liposomal bupivacaine is mixed, so this study aims to provide clearer results through a randomized controlled trial. Participants will receive either a local infiltration of 40 mL of 0.25% bupivacaine hydrochloride alone or a mixture of 20 mL liposomal bupivacaine with 20 mL 0.25% bupivacaine hydrochloride. This infiltration is administered by a thoracic surgeon at the incision site before closing the surgical wound. Postoperatively, all patients have access to patient-controlled analgesia with sufentanil and ondansetron, and if needed, oral oxycodone with acetaminophen or intravenous morphine may be given. The study monitors analgesic use and pain control during the first 72 hours after surgery. Participants will be closely monitored for pain levels using numeric rating scales at rest and during movement at multiple time points up to 3 months after surgery. Researchers will also track the amount of opioid medication used, patient satisfaction, sedation levels, recovery quality, length of hospital stay, and any side effects such as nausea and vomiting. The primary outcome is the amount of morphine-equivalent rescue pain medication used within 48 hours post-surgery. The study is expected to conclude by June 2027, with participants aged 18 to 64 years undergoing elective VATS procedures.
CONDITIONS
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 72 hours postoperatively
Participants undergo video-assisted thoracoscopic surgery and receive either liposomal bupivacaine plus bupivacaine or bupivacaine hydrochloride via local infiltration before incision closure to relieve postoperative pain.
Postoperative monitoring visits at 2, 24, 48, and 72 hours
Duration - 3 months postoperatively
Participants are assessed for pain and recovery at 1 week, 1 month, and 3 months after surgery to monitor longer-term outcomes and medication use.
Visits at 1 week, 1 month, and 3 months
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
F
Fang Luo
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Han-Xue Zhao, Wei Dou, Xin-Tong Meng...
https://pubmed.ncbi.nlm.nih.gov/40760826Mustafa Dikici, Selcan Akesen, Belgin Yavaşcaoğlu...
https://pubmed.ncbi.nlm.nih.gov/34988957